0001193125-21-329814.txt : 20211216 0001193125-21-329814.hdr.sgml : 20211216 20211115160259 ACCESSION NUMBER: 0001193125-21-329814 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20211115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viridian Therapeutics, Inc.\DE CENTRAL INDEX KEY: 0001590750 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 471187261 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 203 CRESCENT STREET STREET 2: BLDG. 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 617.272.4600 MAIL ADDRESS: STREET 1: 203 CRESCENT STREET STREET 2: BLDG. 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: SIGNAL GENETICS, INC. DATE OF NAME CHANGE: 20140710 CORRESP 1 filename1.htm CORRESP

Viridian Therapeutics, Inc.

221 Crescent Street, Suite 401

Waltham, MA 02453

(617) 272-4600

November 15, 2021

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, DC 20549

 

  Re:

Viridian Therapeutics, Inc.

Registration Statement on Form S-3 (File No. 333-260859)

To Whom it May Concern:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Viridian Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above referenced registration statement (the “Registration Statement”) be accelerated to November 17, 2021, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Ryan A. Murr at (415) 393-8373.

 

Very truly yours,
Viridian Therapeutics, Inc.
By:  

/s/ Jonathan Violin, Ph.D.

Name:   Jonathan Violin, Ph.D.
Title:   President and Chief Executive Officer

 

cc:

Ryan A. Murr, Gibson, Dunn & Crutcher LLP

  

Branden C. Berns, Gibson, Dunn & Crutcher LLP